Effect of Qixin Huanwu capsules as adjuvant therapy on the Treg/Th17 immune balance and vascular endothelial function in hypertensive CHD patients with qi deficiency and blood stasis syndrome
CHEN Ningning
CHEN Yanjie
SHI Tanbei
MA Ying
Abstract：Objective To investigate the effects of Qishen Huanwu capsules as adjuvant therapy on the regulatory T cells(Treg)/helper T cell 17(Th17)immune balance and vascular endothelial function in patients with coronary heart disease(CHD)and hypertension presenting with qi deficiency and blood stasis syndrome.Methods From February 2023 to October 2024,91 patients developing CHD and hypertension presenting with qi deficiency and blood stasis syndrome were selected and randomly divided into the combination group(n=45)and the Western medicine group(n=46)using a random number table.The Western medicine group received conventional Western medicine treatment,while the combination group was supplemented with Qishen Huanwu capsules.After 8 weeks of continuous medication,both groups were compared in terms of qi deficiency and blood stasis syndrome score,blood pressure,cardiac function indicators[left ventricular ejection fraction(LVEF),the ratio of early to late diastolic mitral inflow peak velocities(E/A)],Treg/Th1 immune balance status,and vascular endothelial function indicators[endothelin-1(ET-1),nitric oxide(NO)]before and after treatment.Results At 8 weeks after treatment,the qi deficiency and blood stasis syndrome score,systolic blood pressure,and diastolic blood pressure in both groups were lower than those before treatment,and lower in the combination group than in the Western medicine group(P<0.05,P<0.01).At 8 weeks after treatment,the LVEF and E/A in both groups were higher than those before treatment,and higher in the combination group than in the Western medicine group(P<0.05,P<0.01).At 8 weeks after treatment,Treg and Treg/Th17 in both groups were higher than those before treatment,and Th17 was lower than that before treatment(P<0.05);and at 8 weeks after treatment,Treg and Treg/Th17 in the combination group were higher than those in the Western medicine group,and Th17 was lower than that in the Western medicine group(P<0.05,P<0.01).At 8 weeks after treatment,ET-1 in both groups was lower than that before treatment,while NO was higher than that before treatment(P<0.05).At 8 weeks after treatment,ET-1 in the combination group was lower than that in the Western medicine group,while NO was higher than that in the Western medicine group(P<0.01).Conclusion For hypertensive CHD patients with qi deficiency and blood stasis syndrome,Qishen Huanwu capsules as adjuvant therapy can effectively regulate the Treg/Th17 immune balance,significantly improve vascular endothelial function,blood pressure and cardiac function,and significantly alleviate related symptoms.
Keywords：coronary heart diseasehypertensionqi deficiency and blood stasis syndromeQishen Huanwu capsulesimmune balanceleft ventricular ejection fractionendothelin-1nitric oxide
Publication Date：2026-01-28
Online Publishing Date：2026-03-16(First online date of this platform, not the publication date of the document)
Pages：6( 40-45 )